Anoka County in National Study, Shows Survival to Hospital Discharge After Cardiac Arrest Doubles with Improved CPR and Impedance Threshold Device
The EMS departments submitting data in the study tracked individuals whoexperienced cardiac arrest outside of the hospital all the way throughhospital discharge. When subjects were treated with new CPR techniquesincluding the use of the ResQPOD, an Impedance Threshold Device (ITD), thehospital discharge rates jumped from 7.9 percent to 15.7 percent, or doublethe survival rate of the control group.
Aufderheide said, "This menu of interventions for patients with cardiacarrest has resulted in one of the highest overall survival rates everdocumented for this devastating medical condition. It represents a majorbreakthrough in the treatment of cardiac arrest, which we hope will bedisseminated in other systems throughout the United States."
The seven EMS departments participating in the study used AHA-recommendednew CPR including increased compressions, full chest wall recoil and use ofthe impedance threshold device. The ResQPOD ITD is a $99 device that is thesize of a small fist and manufactured by Minnesota-based Advanced CirculatorySystems (ACSI). The Impedance Threshold Device received a Class IIa rating bythe AHA in its 2005 Emergency Cardiac Care Guidelines. This is the highestrecommendation possible given to an intervention that improves hemodynamicsand improves the rate of return of spontaneous circulation after cardiacarrest.
Dr. Keith Lurie, Chief Medical Officer at Advanced Circulatory Systems,said, "There are technologies and practices that we know can move the needleto save more lives. This is especially true when we use these therapiestogether as recommended in the American Heart Association 2005 Guidelines.People should not have to rely on being in the right place at the right timewhen they experience cardiac arrest. While there remains a lot of work tofurther increase survival rates, the findings from this study, that survivalto hospital discharge rates are doubled with this new approach, has greatvalue for all patients who suffer from a cardiac arrest."
More information on Advanced Circulatory Systems and the ResQPOD isavailable at http://www.advancedcirculatory.com or 952-947-9590. For mediainformation, additional data, graphics or interviews with medical staff,contact Joanne Henry at 612-843-2142.
The generally cleared indication for the ResQPOD is a temporary increasein blood circulation during emergency care, hospital, clinic and home use.Studies are ongoing in the United States to evaluate the long-term benefit ofthe ResQPOD for indications related to patients suffering from cardiac arrest,hypotension during dialysis and severe blood loss. The references in thiscommunication are not intended to imply specific outcome-based claims not yetcleared by the US Food and Drug Administration. Clinical study referencesavailable upon request.Cities in the Study: 1. Largo, FL 2. Anoka County, MN 3. Raleigh, NC 4. Omaha, NE 5. Cypress Creek, TX 6. Madison, WI 7. Milwaukee, WI Study data: -- 893 individuals who experienced cardiac arrest -- Control group: 1,424 patients -- Average age: 64 years -- 65 percent were male
You May Also Like